We recently published a paper (1) showing that autophagy may be a plausible therapeutic
target in amyotrophic lateral sclerosis (ALS). Lithium has known neuroprotective properties …

In a pilot clinical study that we recently published we found that lithium administration slows
the progression of Amyotrophic Lateral Sclerosis (ALS) in human patients. This clinical study …

ALS is a devastating neurodegenerative disorder with no effective treatment. In the present
study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 …

In this article we provide an overview of the intersection between amyotrophic lateral
sclerosis (ALS) and the autophagy pathway and discuss the potential protective effects of …

We read with great interest the paper by Fornai et al.(1) on delayed progression of
amyotrophic lateral sclerosis (ALS) with lithium. In this study the results of a small …

Introduction Lithium was proposed in 2008 as an effective candidate in the treatment of ALS
after a report claimed that it was able to delay functional deterioration by 40% and that none …

In a recent issue of PNAS, Fornai et al. reported that lithium has neuroprotective effects in a
mouse model of motor neuron disease. They also reported that lithium seemed to slow …

Background In a pilot study, lithium treatment slowed progression of amyotrophic lateral
sclerosis (ALS). We aimed to confirm or disprove these findings by assessing the safety and …

In a recent issue of The Lancet Neurology, Aggarwal et al.(Citation 1) reported a multicentric,
randomized, double-blind, clinical trial comparing lithium carbonate plus riluzole with …

Background Lithium has neuroprotective effects in cell and animal models of amyotrophic
lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant …